Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M75,085Revenue $M8,264Net Margin (%)11.7Z-Score2.0
Enterprise Value $M96,718EPS $2.7Operating Margin %26.0F-Score6
P/E(ttm))78.9Cash Flow Per Share $4.9Pre-tax Margin (%)14.4Higher ROA y-yY
Price/Book11.110-y EBITDA Growth Rate %10.5Quick Ratio4.9Cash flow > EarningsY
Price/Sales8.85-y EBITDA Growth Rate %55.9Current Ratio5.2Lower Leverage y-yN
Price/Cash Flow11.8y-y EBITDA Growth Rate %136ROA % (ttm)3.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)18.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M342ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 219.2439%Reduce -6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 219.2439%Reduce -24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 219.2439%Reduce -18.50%1,378,606
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 219.2439%New holding295,632
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 219.2439%Reduce -0.47%34,331,973
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 219.2439%Reduce -1.19%1,794,227
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 219.2446%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 219.2446%Add 12.40%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 219.2446%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 219.2446%Add 8.89%10,985,940
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 219.2446%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 219.2446%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 219.2446%Add 0.57%34,494,015
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 219.2446%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 219.2442%Add 8.19%6,050,442
VRXSteve Mandel 2014-06-30 Add0.64%$116.99 - $138.13
($127.6)
$ 219.2442%Add 14.44%10,089,450
VRXJohn Paulson 2014-06-30 Reduce-0.32%$116.99 - $138.13
($127.6)
$ 219.2442%Reduce -49.97%500,300
VRXGeorge Soros 2014-06-30 Add0.29%$116.99 - $138.13
($127.6)
$ 219.2442%Add 185.46%472,187
VRXWallace Weitz 2014-06-30 Reduce-0.19%$116.99 - $138.13
($127.6)
$ 219.2442%Reduce -2.91%1,551,076
VRXChris Davis 2014-06-30 Add0.17%$116.99 - $138.13
($127.6)
$ 219.2442%Add 16.03%3,153,748
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.0111.5view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4838.97view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0659.23view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.7353.04view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7353.04view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.9536.03view
Farmer, RonDirector 2014-11-24Buy1,000$163.9536.03view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2556.78view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.783.25view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.783.25view

Press Releases about VRX :

    Quarterly/Annual Reports about VRX:

    News about VRX:

    Articles On GuruFocus.com
    Submit Questions for Upcoming Q&A With Value Investor Wally Weitz Apr 27 2015 
    Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
    The Top Guru-Held Canadian Stocks Apr 11 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    Pershing Square Holdings: First Annual Report Mar 25 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Ruane, Cunniff & Goldfarb Inc Comments on Valeant Mar 16 2015 
    Ruane, Cunniff & Goldfarb’s Sequoia Fund Q4 2014 Shareholder Letter Mar 16 2015 

    More From Other Websites
    The Barron's 500 May 01 2015
    Are Drug Mergers In Their Final Act? May 01 2015
    Biotech's torrid run may not be over, analyst says May 01 2015
    Biotech's big outlook May 01 2015
    Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers May 01 2015
    Canadian Stocks Rise as Valeant, Base Metals Producers Advance May 01 2015
    Valeant Pharmaceuticals Reports In-Line Earnings, Ups View - Analyst Blog May 01 2015
    VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report Apr 30 2015
    Barclays Calls Valeant Its Top Pick Apr 30 2015
    Pharming Reports on Annual General Meeting of Shareholders Apr 30 2015
    Canada Stocks Slide as Gold Declines Overshadow Valeant Rally Apr 30 2015
    Stifel Raises Valeant PT As Co. Continues To Execute Global Expansion Strategy Apr 30 2015
    Valeant Pharmaceuticals (VRX) Earnings Report: Q1 2015 Conference Call Transcript Apr 30 2015
    Pharming Reports on Financial Results for Q1 2015 Apr 30 2015
    Valeant Beats Q1 Views, Lifts Guidance, Loses CFO Apr 29 2015
    Valeant raises outlook after completing purchase of Salix Apr 29 2015
    Valeant raises outlook after completing purchase of Salix Apr 29 2015
    Valeant Pharmaceuticals: Scoreboard watching Apr 29 2015
    Valeant Beats Q1 Views, Lifts Guidance, But Loses CFO Apr 29 2015
    Drugmaker Valeant raises forecasts, says CFO to leave Apr 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK